6. Parkinson disease Clinical trials / Disease details


Clinical trials : 2,298 Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

  
14 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02337751
(ClinicalTrials.gov)
July 10, 20159/1/2015A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease ParticipantsA Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With LevodopaParkinson's DiseaseDrug: TVP-1012 1mgTakedaNULLCompleted30 Years79 YearsAll198Phase 3Japan
2NCT02337725
(ClinicalTrials.gov)
February 7, 20159/1/2015A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease PatientsA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With LevodopaParkinson's DiseaseDrug: TVP-1012;Drug: PlaceboTakedaNULLCompleted30 Years80 YearsAll244Phase 3Japan
3NCT02337764
(ClinicalTrials.gov)
February 3, 20159/1/2015A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease ParticipantsA Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease PatientsParkinson's DiseaseDrug: TVP-1012 1mgTakedaNULLCompleted30 Years79 YearsAll222Phase 3Japan
4JPRN-JapicCTI-152762
27/1/2015A long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease PatientsA Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients Parkinson's diseaseIntervention name : TVP-1012 (1 mg/day) with levodopa
Dosage And administration of the intervention : TVP-1012 (1 mg/day) once daily, before or after breakfast. A levodopa combination drug will be concomitantly administered in principle without change in the dose regimen throughout the study period from the start of the screening period.
Control intervention name : null
TAKEDA PHARMACEUTICAL COMPANY LTD.NULL3079BOTH215Phase 3NULL
5NCT02337738
(ClinicalTrials.gov)
January 27, 20159/1/2015A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease ParticipantsA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing OffParkinson's DiseaseDrug: TVP-1012 1mg;Drug: TVP-1012 0.5mg;Drug: PlaceboTakedaNULLCompleted30 Years79 YearsAll404Phase 2/Phase 3Japan
6EUCTR2006-005140-89-NL
(EUCTR)
11/12/200601/12/2006A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge studyA PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge study This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson's Disease (PD).
MedDRA version: 9.1;Level: PT;Classification code 10061536
Trade Name: Selegiline HCl 5 PCH
Trade Name: Nardil
Product Name: Rasagiline 1mg tablet
Product Code: TVP-1012
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesilate
Product Name: Rasagiline 2 mg tablet
Product Code: TVP-1012
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesilate
TEVA Pharmaceuticals Industries LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
160Phase 1Netherlands
7EUCTR2005-001416-42-PT
(EUCTR)
07/11/200525/08/2005A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIOA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536
Trade Name: AZILECT
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Teva Pharmaceuticals Industries LtDNULLNot RecruitingFemale: yes
Male: yes
1100Hungary;Portugal;Germany;United Kingdom;Spain;Italy
8EUCTR2005-001416-42-HU
(EUCTR)
27/09/200520/06/2005A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIOA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536
Trade Name: AZILECT
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Teva Pharmaceuticals Industries LtDNULLNot RecruitingFemale: yes
Male: yes
1100Portugal;Hungary;Germany;United Kingdom;Spain;Italy
9EUCTR2005-001416-42-GB
(EUCTR)
15/09/200513/06/2005A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIOA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536
Trade Name: Azilect
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Product Name: Rasagiline
Product Code: TVP-1012
Teva Pharmaceuticals Industries LtDNULLNot Recruiting Female: yes
Male: yes
1100 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noPortugal;Hungary;Spain;Austria;Germany;Italy;United Kingdom
10EUCTR2005-001416-42-DE
(EUCTR)
01/09/200517/10/2005A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIOA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Teva Pharmaceuticals Industries LtDNULLNot RecruitingFemale: yes
Male: yes
1100Portugal;Hungary;United Kingdom;Germany;Spain;Italy
11EUCTR2005-001416-42-AT
(EUCTR)
24/08/200520/07/2005A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIOA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536
Trade Name: AZILECT
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Teva Pharmaceuticals Industries LtDNULLNot RecruitingFemale: yes
Male: yes
1100Portugal;Hungary;Spain;Austria;Germany;Italy;United Kingdom
12EUCTR2005-001416-42-ES
(EUCTR)
28/07/200528/06/2005A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects. Estudio multicéntrico, doble ciego, de inicio randomizado, controlado con placebo, de grupos paralelos, para valorar Rasagilina como una terapia que modifica la enfermedad de Parkinson en pacientes con enfermedad de Parkinson en fase temprana - ADAGIOA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects. Estudio multicéntrico, doble ciego, de inicio randomizado, controlado con placebo, de grupos paralelos, para valorar Rasagilina como una terapia que modifica la enfermedad de Parkinson en pacientes con enfermedad de Parkinson en fase temprana - ADAGIO Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536
Trade Name: AZILECT
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Trade Name: AZILECT
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Trade Name: AZILECT
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Teva Pharmaceuticals Industries LtDNULLNot Recruiting Female: yes
Male: yes
1100 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noPortugal;Hungary;Spain;Austria;Germany;Italy;United Kingdom
13EUCTR2005-001416-42-IT
(EUCTR)
14/07/200521/06/2005A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease SubjectsA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects Neuroprotective early treatment of Parkinson's disease subjects
MedDRA version: 6.1;Level: PT;Classification code 10061536
Product Name: NA
Product Code: NA
Other descriptive name: NA
Product Name: rasagiline
Product Code: TVP-1012
TEVANULLNot RecruitingFemale: yes
Male: yes
Portugal;Hungary;Germany;United Kingdom;Spain;Italy
14NCT00203125
(ClinicalTrials.gov)
October 200013/9/2005A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133)Parkinson's DiseaseDrug: rasagiline mesylate;Other: tyramineTeva Pharmaceutical IndustriesNULLCompletedN/AN/ABoth55Phase 3United States